Activated B Cells Mediate Efficient Expansion of Rare Antigen-Specific T Cells

Human Immunology

Volumn 68, Issue 2, 2007, Pages 75-85

  Zentz, Caroline ^a   Wiesner, Martina ^a   Man, Stephen ^c   Frankenberger, Bernhard ^a   Wollenberg, Barbara ^d   Hillemanns, Peter ^e   Zeidler, Reinhard ^b   Hammerschmidt, Wolfgang ^a   Moosmann, Andreas ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Activated B cells; antigen presenting cells; CD8 T cells; HLA peptide tetramers; immunotherapy

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN; PROTEIN E7; T LYMPHOCYTE RECEPTOR; TYROSYLMETHIONYLLEUCYLAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IN VITRO STUDY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; ONCOGENE PROTEINS, VIRAL; SPECIES SPECIFICITY; T-LYMPHOCYTE SUBSETS;

EID: 33847100649     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2006.12.004     Document Type: Article

References (38)

1. Cassell D.J., and Schwartz R.H. A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med 180 (1994) 1829
2. Banchereau J., de Paoli P., Valle A., Garcia E., and Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251 (1991) 70
3. Garrone P., Neidhardt E.M., Garcia E., Galibert L., van Kooten C., and Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 182 (1995) 1265
4. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., Delgado J.C., Gribben J.G., and Nadler L.M. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100 (1997) 2757
5. Kondo E., Topp M.S., Kiem H.P., Obata Y., Morishima Y., Kuzushima K., Tanimoto M., Harada M., Takahashi T., and Akatsuka Y. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 169 (2002) 2164
6. von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., Xia Z., Zeng W.Y., Wucherpfennig K.W., Nadler L.M., and Schultze J.L. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99 (2002) 3319
7. Lapointe R., Bellemare-Pelletier A., Housseau F., Thibodeau J., and Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63 (2003) 2836
8. von Bergwelt-Baildon M., Schultze J.L., Maecker B., Menezes I., and Nadler L.M. Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 64 (2004) 4055 Cancer Res 2003;63:2836-43
9. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12
10. Wiest T., Schwarz E., Enders C., Flechtenmacher C., and Bosch F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21 (2002) 1510
11. de Jong A., van der Hulst J.M., Kenter G.G., Drijfhout J.W., Franken K.L., Vermeij P., Offringa R., van der Burg S.H., and Melief C.J. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 114 (2005) 274
12. Santin A.D., Hermonat P.L., Ravaggi A., Chiriva-Internati M., Zhan D., Pecorelli S., Parham G.P., and Cannon M.J. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73 (1999) 5402
13. Youde S.J., McCarthy C.M., Thomas K.J., Smith K.L., and Man S. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 114 (2005) 606
14. Hoffmann T.K., Arsov C., Schirlau K., Bas M., Friebe-Hoffmann U., Klussmann J.P., Scheckenbach K., Balz V., Bier H., and Whiteside T.L. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118 (2006) 1984
15. Youde S.J., Dunbar P.R., Evans E.M., Fiander A.N., Borysiewicz L.K., Cerundolo V., and Man S. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 60 (2000) 365
16. Schreurs M.W., Scholten K.B., Kueter E.W., Ruizendaal J.J., Meijer C.J., and Hooijberg E. in vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 171 (2003) 2912
17. Evans C., Bauer S., Grubert T., Brucker C., Baur S., Heeg K., Wagner H., and Lipford G.B. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 42 (1996) 151
18. Kempkes B., Pich D., Zeidler R., and Hammerschmidt W. Immortalization of human primary B lymphocytes in vitro with DNA. Proc Natl Acad Sci U S A 92 (1995) 5875
19. Moosmann A., Khan N., Cobbold M., Zentz C., Delecluse H.J., Hollweck G., Hislop A.D., Blake N.W., Croom-Carter D., Wollenberg B., Moss P.A., Zeidler R., Rickinson A.B., and Hammerschmidt W. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 100 (2002) 1755
20. Boursnell M.E., Rutherford E., Hickling J.K., Rollinson E.A., Munro A.J., Rolley N., McLean C.S., Borysiewicz L.K., Vousden K., and Inglis S.C. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14 (1996) 1485
21. Wiesner M., Zentz C., Hammer M.H., Cobbold M., Kern F., Kolb H.J., Hammerschmidt W., Zeidler R., and Moosmann A. Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines. Eur J Immunol 35 (2005) 2110
22. Steinle A., Reinhardt C., Jantzer P., and Schendel D.J. In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: evidence for maintenance of an oligoclonally dominated allospecificity by persistent stimulation with an autologous MHC/peptide complex. J Exp Med 181 (1995) 503
23. Toyonaga B., Yoshikai Y., Vadasz V., Chin B., and Mak T.W. Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain. Proc Natl Acad Sci U S A 82 (1985) 8624
24. Arden B., Clark S.P., Kabelitz D., and Mak T.W. Human T-cell receptor variable gene segment families. Immunogenetics 42 (1995) 455
25. Rubio-Godoy V., Dutoit V., Rimoldi D., Lienard D., Lejeune F., Speiser D., Guillaume P., Cerottini J.C., Romero P., and Valmori D. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A 98 (2001) 10302
26. Blomberg K., Hautala R., Lovgren J., Mukkala V.M., Lindqvist C., and Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 193 (1996) 199
27. Alexander-Miller M.A. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 31 (2005) 13
28. Ressing M.E., Sette A., Brandt R.M., Ruppert J., Wentworth P.A., Hartman M., Oseroff C., Grey H.M., Melief C.J., and Kast W.M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154 (1995) 5934
29. Nilges K., Hohn H., Pilch H., Neukirch C., Freitag K., Talbot P.J., and Maeurer M.J. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 77 (2003) 5464
30. Albers A., Abe K., Hunt J., Wang J., Lopez-Albaitero A., Schaefer C., Gooding W., Whiteside T.L., Ferrone S., DeLeo A., and Ferris R.L. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65 (2005) 11146
31. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 32 Suppl 1 (2005) S16
32. Blohm U., Roth E., Brommer K., Dumrese T., Rosenthal F.M., and Pircher H. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 169 (2002) 5522
33. Tan L.C., Gudgeon N., Annels N.E., Hansasuta P., O'Callaghan C.A., Rowland-Jones S., McMichael A.J., Rickinson A.B., and Callan M.F. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 162 (1999) 1827
34. Evans M., Borysiewicz L.K., Evans A.S., Rowe M., Jones M., Gileadi U., Cerundolo V., and Man S. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 167 (2001) 5420
35. Hill S.C., Youde S.J., Man S., Teale G.R., Baxendale A.J., Hislop A., Davies C.C., Luesley D.M., Blom A.M., Rickinson A.B., Young L.S., and Eliopoulos A.G. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 174 (2005) 41
36. Scholten K.B., Schreurs M.W., Ruizendaal J.J., Kueter E.W., Kramer D., Veenbergen S., Meijer C.J., and Hooijberg E. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 114 (2005) 119
37. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 (2003) 138
38. Schultze J.L., Grabbe S., and von Bergwelt-Baildon M.S. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 25 (2004) 659